As of Friday close, Asensus Surgical Inc.’s (AMEX:ASXC) stock was up $0.01, moving up 3.93 percent to $0.39. The average number of shares traded per day over the past five days has been 4,108,280 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0134 gain in that time frame. In the last twenty days, the average volume was 3,166,370, while in the previous 50 days, it was 3,120,248.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ASXC stock retreated -27.91%. Shares of the company fell to $0.3500 on 05/12/22, the lowest level in the past month. A 52-week high of $3.75 was reached on 01/04/22 after having rallying from a 52-week low of $0.35. Since the beginning of this year, ASXC’s stock price has dropped by -64.46% or -$0.7155, and marked a new high 2 times. However, the stock has declined by -89.48% since its 52-week high.
Asensus Surgical Inc. (ASXC) last reported insider trading activity 60 days ago on Mar 15. Kwo Elizabeth, the Director of the company, purchased of 18,000 shares for $0.53 on Mar 15. It resulted in a $9,558 investment by the insider. Milne David Bruce added 225,000 shares at an average price of $0.62 on Mar 07. The insider now owns 619,884 shares following the transaction. On Mar 04, Director Milne David Bruce bought 150,000 shares at $0.64 apiece. The transaction was valued at $95,745.
The stock’s beta is 1.67. Besides these, the trailing price-to-sales (P/S) ratio of 11.77, the price-to-book (PB) ratio of 0.62.
In the three months ended September 29, Asensus Surgical Inc.’s quick ratio stood at 12.70, while its current ratio was 13.70, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is -34.80% percent. Based on annual data, ASXC earned -$2.86 million in gross profit and brought in $8.23 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -36.60%. Return on equity (ROE) for the past 12 months was -36.90%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ASXC’s revenue fell -94.39% to $2.48 million during the quarter, while net income inched up to $1.07 million. While analysts expected Asensus Surgical Inc. to report -$0.06 quarterly earnings, the actual figure was -$0.06 per share. During the quarter, the company generated -$15.2 million in EBITDA. The liabilities of Asensus Surgical Inc. were 15.73 million at the end of its most recent quarter ended September 29, and its total debt was $4.56 million. The value of shareholders’ equity is $236.46 million.
This quick technical analysis looks at Asensus Surgical Inc.’s (ASXC) price momentum. With a historical volatility rate of 90.71%, the RSI 9-day stood at 38.62% on 13 May.
With respect to its five-day moving average, the current Asensus Surgical Inc. price is up by +3.52% percent or $0.0134. At present, ASXC shares trade -24.87% below its 20-day simple moving average and -65.09% percent below its 100-day simple moving average. However, the stock is currently trading approximately -36.88% below its SMA50 and -82.85% below its SMA200.
Stochastic coefficient K was 18.02% and Stochastic coefficient D was 16.04%, while ATR was 0.0441. Given the Stochastic reading of 29.10% for the 14-day period, the RSI (14) reading has been calculated as 36.71%. As of today, the MACD Oscillator reading stands at -0.0160, while the 14-day reading stands at -0.0373.
H.C. Wainwright launched its rating on Asensus Surgical Inc. (AMEX: ASXC) to a Buy in a note to investors on May 26, 2021. Asensus Surgical Inc. (ASXC) has been rated Buy by analysts. According to 0 brokerage firms, ASXC is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Asensus Surgical Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $4.00, the current consensus forecast for the stock is $4.00 – $4.00. Based on these forecasts, analysts predict Asensus Surgical Inc. (ASXC) will achieve an average price target of $4.00.